LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia

Written By Mollie Rotmensch

Anami Y. et al. Mol. Cancer. Ther. 2020; 19: 2330–2339.

Mollie Rotmensch
Previous

Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4)

Next

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells